Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading 1.3% Higher

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) shares traded up 1.3% on Monday . The company traded as high as $88.91 and last traded at $88.68. 533 shares changed hands during trading, a decline of 77% from the average session volume of 2,311 shares. The stock had previously closed at $87.55.

Analyst Upgrades and Downgrades

Separately, BTIG Research started coverage on shares of Zealand Pharma A/S in a research report on Thursday, March 7th. They issued a "buy" rating on the stock.

Zealand Pharma A/S Stock Performance

The firm's 50 day simple moving average is $92.94 and its 200 day simple moving average is $72.75. The firm has a market capitalization of $4.57 billion, a price-to-earnings ratio of -48.72 and a beta of 0.67.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.08). Zealand Pharma A/S had a negative net margin of 213.77% and a negative return on equity of 41.49%. The firm had revenue of $3.35 million during the quarter, compared to analyst estimates of $1.97 million. As a group, sell-side analysts forecast that Zealand Pharma A/S will post -2.56 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.